The Institut Bordet Clinical Haematology Department specialises in determining and treating diseases of the blood.
The Institut Bordet is committed to the treatment of these diseases and to offering patients high-quality, individual treatment.
In addition to the traditional approach to blood diseases, the Institut is also engaged in the development of innovative and complex techniques and therapies.
The Institut’s mission covers three main university fields: clinical, research and teaching.
The multidisciplinary nature of the Department, in both its diagnostic and therapeutic approaches, forms an integral part of all decisions concerning the patient.
The expertise of the Clinical Haematology Department includes the treatment of:
- high and low grade lymphoma
- multiple myeloma and associated conditions (POEMS syndrome, amyloidosis, etc)
- acute and chronic leukaemia
- myelodysplastic syndromes, myeloproliferative syndromes (chronic myeloid leukemia, Vaquez disease, essential thrombocytosis, myelofibrosis).
The Department has at its disposal all the modern technology needed to ensure the highest level of care:
- sterile isolation facilities for neutropenic patients following chemotherapy or after medullary aplasia of other origin
- stem cell transplant treatment
- development of new transplant techniques (non-myeloablative, T-cell depleted, haploidentical)
- cord blood bank for the ULB
- cytapheresis and photopheresis
- cell therapy.
In addition, in order to offer patients the most innovative treatments, the Department is involved in clinical research activities:
- in collaboration with the EORTC, LYSA, IFM and EBMT in the treatment of malignant haemopathies
- in collaboration with the EORTC in relation to associated infectious diseases
DOCTEUR DOMINIQUE BRON of iris-Hopitaux-Ziekenhuizen on Vimeo.
National and international approvals
- since 2006: "JACIE" for haematopoietic stem cell transplants in adults and children
- since 2012: Netcord/FACT accreditation for the cord blood bank
- since 2011: AFMPS for the "banking" of haematopoietic stem cells, cord blood and mesenchymatous cells.
The Department’s specific activities include:
- therapeutic photopheresis for Graft Versus Host Disease
- haploidentical transplants
- new cell immunotherapy protocols (TCAR)
- myeloma clinic comprising doctors (haematologist, radiologist, radiotherapist, surgeon, pain specialist) and paramedical staff (psychologist, dietician, nurse coordinator) specialising in the treatment of this disease.
- expertise in chronic lymphoid leukaemia for over 30 years in close collaboration with research laboratories (prognostic factors, microenvironment, new drug activity, etc) and in clinical research (clinical studies, access to new drugs)
- lymphoma: research in close collaboration with the French group LYSA
- acute leukaemia and myelodysplastic syndromes: international therapeutic protocols (EORTC, GRAALL, APL, HOVON, etc)
Our commitment to teaching is at all levels of training: medical students, BioMed BACH3 students, oncology nurses, EHA Master Classes, GPs, doctors undergoing specialised training, paramedics and the general public.
These duties are shared between Professors Dominique Bron, Nathalie Meuleman, Philippe Lewalle, Sebastian Wittnebel and Marie Maerevoet.
Research projects
Participation of the Hematology Department in research projects with the following laboratories :
EXPERIMENTAL HAEMATOLOGY LABORATORY (HEMEXP)
CLINICAL CELLULAR THERAPY RESEARCH LABORATORY (LTCC)
Project 1
The prognostic value of cognitive function, biomarkers of ageing and clinical factors in elderly patients with malignant haemopathy admitted for chemotherapy (Dominique Bron, MD, PhD)
- Project leader : Dominique Bron
- Collaborations : H. Wildiers, M. Delforge (KUL)
- Funding : Télévie, FNRS, Fonds Yvonne Boël
Project 2
Interculturality and Transplantation
- Project leaders : Sandra Michiels, Patrick Crombez
- Collaboration : MASCC (International, Prof Klastersky)
- Funding : Les Amis de l’Institut Bordet / BHS / Fondation Kisane
Project 3
Role of radio-immunotherapy in myeloma
- Project leaders : Nathalie Meuleman, Marie Vercruyssen, Patrick Flamen
- Funding : Les Amis de l’Institut Bordet
Project 4
Protocoles de recherche clinique académiques et pharmaceutiques
- Project leaders : Dominique Bron and colleagues
- Funding : Fonds Ariane, Pharma
Our team
Head of Department
- Prof Nathalie Meuleman - Haematological Medicine (multiple myeloma and plasmocytary disorders, autografts)
Heads of Clinic
- Prof Philippe Lewalle - Haematological Medicine (myeloproliferative syndrome, chronic myeloid leukaemia and allogeneic transplants)
- Prof Sebastian Wittnebel - Haematological Medicine (leukaemia, myelodysplasia, new drugs and allogeneic transplants)
- Dr Marie Maerevoet - Haematological Medicine (lymphomas and lymphoproliferative disorders, new drugs, autografts)
- Dr Cécile Springael - Haematological Medicine (T lymphomas and rare lymphomas)
Professor Emeritus
Prof Dominique Bron - Haematological Medicine (rare lymphoma and chronic lymphoid leukaemia)
Resident
- Dr Marie Vercruyssen - Haematological Medicine (multiple myeloma and plasmocytic disorders, autografts)
- Dr Chloé Spilleboudt - Haematological Medicine (leukemias, myelodysplasias and allogeneic transplantations)
- Dr Adriano Salaroli - Haematological Medicine (myeloproliferative syndromes, myelodisplasia, acute leukemias and transplantations, apheresis)
- Dr Fulvio Massaro
Head Nursing (Tel : +32 (0)2 541 33 55)
- Patrick Crombez
Nursing «coordinator of allografts » (Tel : +32 (0)2 541 33 30)
- Marie-France Jaivenois
- Rezarta Ayazi
Nurses (health care coordinators) (Tel : +32 (0)2 541 73 94)
- Sophie Delaunois
- Zilfi Balci
- Julie Kiss
Apheresis unit and Stem Cell Collection (Tel : +32 (0)2 541 32 11)
- Philippe Lewalle - Responsible physician
- Adriano Salaroli - Resident
- Corine Mal - Nurse (Tel : +32 (0)2 541 32 74)
- Walter Bellemans - Nurse
- Munteanu Nicoleta - Nurse
- Olivier Mugema - Nurse
- Denise Duthoit - Nurse
Transplantation Coordination (Tel : +32 (0)2 541 32 12)
- Sandra Michiels - Coordinator
- Redouane Rouas - Suppleant
- Anne De Meuter - Data Manager EBMT
Hematology Clinical Research Unit
- Sabrina Costantini - Head (Tel : +32 (0)2 541 36 47)
- Dominique De Poorter - Nurse (Tel : +32 (0)2 541 35 98)
- Delphine Léva - Nurse (Tel : +32 (0)2 541 33 57)
- Lina Adu Poku - Nurse (Tel : +32 (0)2 541 39 11)
- Aude Bovenkamp - Administrative (Tel : +32 (0)2 541 72 05)
Quality Cell
- Aurélie Timmermans (Tel +32 (0)2 541 72 25)
Secretariat
- Sabine Ackermans (Administration) - Tel : +32 (0)2 541 37 28
- Jennifer Marinus (Consultation) - Tel : +32 (0)2 541 36 84
- Nancy Martin (Consultation) - Tel : +32 (0)2 541 38 78
- Marie-France Ebanga (Consultation) - Tel : +32 (0)2 541 36 84
25/02/2021
Scientific publications
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.
Authors : Zijlstra JM, Follows G, Casasnovas RO, Vermaat JSP, Kalakonda N, Choquet S, Hill B, Thieblemont C, Cavallo F, Cruz F, Kuruvilla J, Hamad N, Jaeger U, Caimi P, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Schuster M, Egyed M, Offner F, Vassilakopoulos TP, Samal P, Ku M, Xu J, Corona K, Chamoun K, Shah J, Canales M, Maerevoet M
Year : 2022
Journal : Cancers (Basel)
Volume : 14
New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy.
Authors : Andreozzi F, Massaro F, Wittnebel S, Spilleboudt C, Lewalle P, Salaroli A
Year : 2022
Journal : Int J Mol Sci
Volume : 23
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.
Authors : Bobin A, Kyheng M, Guidez S, Gruchet-Merouze C, Richez V, Duhamel A, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Perrot A, Roussel M, Jaccard A, Petillon MO, Belhadj-Merzoug K, Chretien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Moreau P, Avet-Loiseau H, Hulin C, Facon T, Leleu X
Year : 2022
Journal : Leukemia
Volume : 36
Pages : 881-884
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
Authors : Leupin N, Zinzani PL, Morschhauser F, Dalle S, Maerevoet M, Michot JM, Ribrag V, Offner F, Beylot-Barry M, Moins-Teisserenc H, Zwaenepoel K, de Winne K, Battistella M, Hultberg A, Gandini D, Moshir M, Jacobs J, Delahaye T, Khan A, Zabrocki P, Silence K, Van Rompaey L, Borg C, Motta G, Melle F, Calleri A, Pauwels P, de Haard H, Pileri S, Bagot M
Year : 2022
Journal : Cancer
Volume : 128
Pages : 1004-1014
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.
Authors : Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart M, Roblin E, Michiels S
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 3